The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response - Wikidata - awgldk - TriplyDB

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

http://www.wikidata.org/entity/Q36928556

about

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.The CYP2C19*17 variant is not independently associated with clopidogrel response.Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways.Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists.Genetics of platelet inhibitor treatment Cardiovascular pharmacogenomics: expectations and practical benefits.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.Pharmacogenomics of oral antiplatelet drugs.Pharmacogenetics of antiplatelet therapy.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Regulations of Xenobiotics and Endobiotics on Carboxylesterases: A Comprehensive Review.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Clopidogrel pharmacogenetics: Beyond candidate genes and genome-wide association studies.Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.

P2860

Q26801867-FAE0C466-84A8-44FB-BFDF-671D30993F93 Q26822796-C0ACB9A2-1899-4988-9438-82E42F0C5CC3 Q27022443-C117CDD4-B495-45B3-8D61-1C60E0C5E080 Q30373969-B12BDA50-FFCD-4E50-80FF-D8CE6AEAE765 Q33596716-D8B91544-E28C-4CA5-B94B-F545F5C04BF0 Q33963651-E0351BEC-B20C-40E4-A00E-9CDFAC42862A Q36125455-7ECDD723-45B0-4C74-A033-BB2987472BEE Q36243667-F08C5137-80AD-4E19-B28F-3ED4560E7A61 Q36599251-387FE9DC-56F1-40D7-91AF-33EA4556C212 Q36736998-64CD8901-60A0-4BAE-9D4E-9118ED69806E Q36767978-021B03AC-A448-4F72-B08C-3D1C5C3D56DA Q37025611-05E6A9D0-94CF-4464-B8E8-5850820608C1 Q37171415-11B77509-FC15-46AA-9B03-4DF79087D3EE Q37390889-62918E47-655E-4186-A0E5-90B7898148FC Q37700662-B5A574DF-D2A8-4A68-97B4-313E60F16E96 Q37708007-2ACF37D5-2B39-41C7-84BA-EF9C2FF433D7 Q37724614-6AB9386A-008C-46D5-9F39-8017708011C5 Q38116753-5878B5D7-EACC-4DE6-AFEC-F3851F27B16F Q38117748-4FE7923F-2226-417B-AB8C-EB1A96EED246 Q38131848-89A44F38-8FB0-4090-AFE4-3F40C2994CB6 Q38169969-3A8377C5-2E54-4172-ABE1-7ECEF152EA04 Q38177048-F8B8C6A6-3CAD-4844-877F-A30120C7AC95 Q38195628-7A8C4FE1-4F6E-485A-9ABE-76F7DA21DEA8 Q38199010-761433C2-2CDB-4B74-AECB-43BE60C532B6 Q38307535-C96CE5F8-07EA-4D8E-8D4F-5CB5B9BBB6A4 Q38380508-D6C26232-ECFF-421B-ACC7-379A85D1E341 Q38401281-F6D65C11-97C4-433B-81F7-FF45DD3CE706 Q38444425-8F6F773B-32AD-4702-B0EB-1352C78C19BD Q38644870-90F4DD5D-0E94-4E51-B358-DDB50FB94677 Q38749602-2304DBA5-BBA2-45AE-A743-8696AA4BADB2 Q38750444-57EF31E0-E982-47C4-8A7E-E01B98E32CFD Q38756642-0C8ABF50-613D-43F1-A87F-3623122AC65E Q38798449-D43A0710-F0EC-424C-AA57-125423B4C505 Q38863876-69E3BCD7-E901-4EA9-8127-CCF6B689FFEE Q39145949-CA807C8C-A14A-4EC3-B11C-BD91006A46A2 Q39249688-ECC32579-1A04-4567-8E93-5E61F1574231 Q39370301-AA213D12-2A57-4E98-9237-869E552A0496 Q39404447-F41F49A5-2CBA-4CD6-9703-2D70E80B4507 Q40366712-E62A3B1D-1D33-473C-A1AC-8E0EE4D30A4C Q40734518-E67931A5-DF42-41CA-8F02-1B848D85F5E8

P2860

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

http://www.wikidata.org/entity/Q36928556

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The functional G143E variant o ...... d greater clopidogrel response

@en

type

label

The functional G143E variant o ...... d greater clopidogrel response

@en

prefLabel

The functional G143E variant o ...... d greater clopidogrel response

@en

P1433

Q36928556-F5D371CB-F573-4E20-9F18-BFE035B3C68A

P1476

Q36928556-77607FF2-0CD5-4E21-84CA-7DF2E14D1C2D

P2093

Q36928556-02CBE443-D42D-460F-9E27-72B57486CADA

Q36928556-10D83743-7107-4A85-8C5F-9491FA7A274A

Q36928556-2425E184-E983-48F0-987E-053E54E3BD11

Q36928556-3D3A3EA2-715C-48D6-8D99-49A5F1D4B728

Q36928556-62AE0201-1220-490B-994C-A3CBB5ADCA48

Q36928556-9DD0EAFB-1A08-424A-A31A-7F2D01115BD6

Q36928556-A3839F99-E7C5-4EA6-9A57-D2968AA5C925

Q36928556-A4FEABE7-6132-40D6-BD28-6BED9CABD1FE

Q36928556-A58DC8BA-5C76-4AFF-BBA9-D7F5D5B0C3D0

Q36928556-AD6D3A47-9D3B-41A8-A136-AF0C366D7378

P2860

Q36928556-09D0905C-171F-4520-B1D6-AF801E51594D

Q36928556-1602BA6A-F0A3-47A8-B617-8153DE7A3C24

Q36928556-19657E3B-D40A-48EF-82C7-5E4829CB8B29

Q36928556-2360E869-B936-4FE5-9DB8-8DCE1DC84371

Q36928556-278E41DB-2C83-4532-8A1E-E5397F60F105

Q36928556-40FEEB69-14C5-43DD-867B-BAE41143B7BF

Q36928556-4D6C218F-D586-4288-87BD-0CF0197176DD

Q36928556-58AC0124-C075-490E-87F7-F686CC741536

Q36928556-5F7EAF0F-6C8B-4BC3-A817-6FB4725E5640

Q36928556-60ED3E88-756A-47D5-85C9-FCF5F5C335BE

P304

Q36928556-9632B7C0-0B8B-4F12-976B-D567A559F6BE

P31

Q36928556-E0490F7E-A1BF-4CCF-B0D3-977385365D67

P356

Q36928556-B7F6FADB-62D7-4E5A-8994-560C6104D2BE

P433

Q36928556-E1E4B780-9105-48A0-A37C-504839CCF82F

P478

Q36928556-001C25AB-8295-415F-A3BE-69A532ADB832

P50

Q36928556-BCD1E040-81F4-469C-8E6C-F8F3E6C50726

Q36928556-DC6B54D7-D05D-4737-A19A-A402CCF92B43

P577

Q36928556-7DBF90C1-4711-4428-93CE-4D41DA2666FE

P698

Q36928556-ECFEFD5C-9209-4566-AC2F-A9B5AEB43059

P921

Q36928556-A47292D0-09C5-4D56-B867-EA192932CFF5

P932

Q36928556-9F823267-02C6-438C-90F7-93FEE3633F39

P356

FPC.0B013E32835AA8A2

P1433

Pharmacogenetics and Genomics

P1476

The functional G143E variant o ...... d greater clopidogrel response

@en

P2093

Cody J Peer

http://www.w3.org/2001/XMLSchema#string

Jeffrey R O'Connell

http://www.w3.org/2001/XMLSchema#string

Joshua P Lewis

http://www.w3.org/2001/XMLSchema#string

Kathleen Ryan

http://www.w3.org/2001/XMLSchema#string

Keith Tanner

http://www.w3.org/2001/XMLSchema#string

Kevin P Bliden

http://www.w3.org/2001/XMLSchema#string

Michael A Pacanowski

http://www.w3.org/2001/XMLSchema#string

Paul A Gurbel

http://www.w3.org/2001/XMLSchema#string

Quince Gibson

http://www.w3.org/2001/XMLSchema#string

Richard B Horenstein

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of human esterase D: a potential genetic marker of retinoblastoma

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients

Functional and structural features of the oxyanion hole in a thermophilic esterase from Alicyclobacillus acidocaldarius

Structural characterization and reversal of the natural organophosphate resistance of a D-type esterase, Saccharomyces cerevisiae S-formylglutathione hydrolase

Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice

Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril

Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E32835AA8A2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Braxton D. Mitchell

Alan R. Shuldiner

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23111421

http://www.w3.org/2001/XMLSchema#string

P921

P932

3682407

http://www.w3.org/2001/XMLSchema#string